Misbahuddin Siddiqui, MD
Pulmonary Disease · Huntsville, ALNPI 1114028271
Payments from drug & device makers
Across 651 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Boehringer Ingelheim$543
- Mylan Specialty L.p.$448
- Genentech USA, Inc.$440
- plus $4K from 30 others
What the payments were for
- Food & beverage$11,74599%
- Education$921%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 212 | $3,088 |
| AstraZeneca | 130 | $2,459 |
| Regeneron Healthcare Solutions, Inc. | 46 | $1,021 |
| Boehringer Ingelheim | 30 | $543 |
| Mylan Specialty L.p. | 23 | $448 |
| Genentech USA, Inc. | 27 | $440 |
| Grifols USA, LLC | 20 | $392 |
| Amgen | 14 | $319 |
| Insmed, Inc. | 13 | $314 |
| Sanofi | 12 | $313 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $304 |
| Harmony Biosciences LLC | 7 | $191 |
| Sunovion Pharmaceuticals Inc. | 13 | $190 |
| Novartis | 9 | $184 |
| Actelion Pharmaceuticals US, Inc. | 8 | $176 |
| Gilead | 9 | $163 |
| Philips North America LLC | 7 | $150 |
| Cumberland Pharmaceuticals, Inc. | 3 | $140 |
| Viatris Specialty LLC | 5 | $133 |
| Pulmonx Corporation | 5 | $97 |
| ANI Pharmaceuticals, Inc. | 3 | $90 |
| Inspire Medical Systems, Inc. | 3 | $80 |
| Jazz Pharmaceuticals Inc. | 5 | $80 |
| Lilly USA, LLC | 3 | $71 |
| Astellas Pharma US Inc | 4 | $68 |
| Electromed, Inc. | 5 | $64 |
| Merck | 4 | $57 |
| La Jolla Pharmaceutical Company | 4 | $54 |
| United Therapeutics Corporation | 3 | $51 |
| Nestle Healthcare Nutrition Inc. | 2 | $34 |
| CSL Behring | 2 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Optinose US, Inc. | 1 | $22 |
| Verona Pharma, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$11,837 in reported general payments places this provider in the 75th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 921 | $684,430 |
| Spiriva RespimatTiotropium Bromide | 371 | $220,286 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 273 | $200,995 |
| Breo ElliptaFluticasone/Vilanterol | 419 | $184,368 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 208 | $117,386 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $78,157 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 74 | $40,398 |
| SymbicortBudesonide/Formoterol Fumarate | 104 | $34,142 |
| Advair HfaFluticasone Propion/Salmeterol | 66 | $29,965 |
| Incruse ElliptaUmeclidinium Bromide | 64 | $29,380 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 177 | $26,311 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 116 | $25,733 |
| XolairOmalizumab | 12 | $21,011 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $20,022 |
| DuleraMometasone/Formoterol | 30 | $16,334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $3,088 | $1,024,5481,640 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $543 | $280,706461 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,459 | $235,137377 claims |
| Grifols USA, LLCProlastin C | $392 | $78,15712 claims |
| MerckDulera | $57 | $16,33430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Huntsville
- Luther CorleyHuntsville$86K
- Roshen MathewHuntsville$19K
- Murthy VuppalaHuntsville$16K
- Richard SneeringerHuntsville$14K
- Saketh Palasamudram ShekarHuntsville$11K
- Robert GarverAndalusia$4.6M
- Allan SeibertMobile$2.4M
- Tejaswini KulkarniBirmingham$1.7M
- Jan WestermanJasper$834K
- Bryan GarciaBirmingham$606K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.